The FDA has granted fast track designation to the selective HDAC8 inhibitor NBM-BMX for use as a therapeutic option in patients with metastatic uveal melanoma, according to an announcement from NovelWise Pharmaceutical Corporation.1
The agent is…
The FDA has granted fast track designation to the selective HDAC8 inhibitor NBM-BMX for use as a therapeutic option in patients with metastatic uveal melanoma, according to an announcement from NovelWise Pharmaceutical Corporation.1
The agent is…